Nutriband Inc. (NTRB): Price and Financial Metrics
GET POWR RATINGS... FREE!
NTRB Stock Summary
- The ratio of debt to operating expenses for NUTRIBAND INC is higher than it is for about just 7.63% of US stocks.
- NTRB's price/sales ratio is 14.49; that's higher than the P/S ratio of 92.65% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.09 for NUTRIBAND INC; that's greater than it is for just 8.03% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to NUTRIBAND INC are VISL, CDLX, FUBO, PTON, and BLFS.
- NTRB's SEC filings can be seen here. And to visit NUTRIBAND INC's official web site, go to nutriband.com.
NTRB Valuation Summary
- In comparison to the median Healthcare stock, NTRB's price/earnings ratio is 119.48% lower, now standing at -4.5.
- NTRB's price/earnings ratio has moved up 174.1 over the prior 61 months.
Below are key valuation metrics over time for NTRB.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| NTRB | 2022-12-05 | 14.6 | 3.1 | -4.5 | -4.2 |
| NTRB | 2022-12-02 | 15.2 | 3.2 | -4.7 | -4.3 |
| NTRB | 2022-12-01 | 17.8 | 2.9 | -4.2 | -3.9 |
| NTRB | 2022-11-30 | 17.9 | 2.9 | -4.2 | -3.9 |
| NTRB | 2022-11-29 | 18.1 | 3.0 | -4.3 | -4.0 |
| NTRB | 2022-11-28 | 18.1 | 3.0 | -4.3 | -4.0 |
NTRB Price Target
For more insight on analysts targets of NTRB, see our NTRB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $24.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
NTRB Stock Price Chart Interactive Chart >
NTRB Price/Volume Stats
| Current price | $3.82 | 52-week high | $12.18 |
| Prev. close | $3.75 | 52-week low | $2.81 |
| Day low | $3.60 | Volume | 8,628 |
| Day high | $3.90 | Avg. volume | 193,636 |
| 50-day MA | $4.01 | Dividend yield | N/A |
| 200-day MA | $4.25 | Market Cap | 29.92M |
Nutriband Inc. (NTRB) Company Bio
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida
Latest NTRB News From Around the Web
Below are the latest news stories about NUTRIBAND INC that investors may wish to consider to help them evaluate NTRB as an investment opportunity.
Nutriband Inc. Reports Record Revenue Up 118% YoY in Q3Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced financial and operational results for the third quarter ended October 31, 2022. |
Nutriband Inc.'s (NASDAQ:NTRB) CEO Compensation Looks Acceptable To Us And Here's WhyShareholders may be wondering what CEO Gareth Sheridan plans to do to improve the less than great performance at... |
Nutriband Inc to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW)today announces that Gareth Sheridan, CEO, will be presenting at the RHK Capital Disruptive Growth Conference in New York City on Monday, December 5 at 10:20 AM. |
Nutriband Receives Notice of Issuance from the Canadian Intellectual Property Office for its AVERSA(TM) Abuse Deterrent Transdermal Technology PatentNutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced that the Canadian Intellectual Property Office (CIPO) has granted Canadian patent No. 2,937,649, entitled "Abuse and Misuse Deterrent Transdermal Systems," with an issue date of November 1, 2022. |
Nutriband Supports Newly Published CDC Opioid Prescribing GuidelinesNutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) supports the new United States Centers for Disease Control and Prevention (CDC) clinical practice guideline entitled "CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022" published on November 4, 2022.1 These guidelines are an update to the 2016 clinical practice guideline and allows prescribers to implement comprehensive and holistic pain management including responsible |
NTRB Price Returns
| 1-mo | 0.53% |
| 3-mo | -10.12% |
| 6-mo | -1.55% |
| 1-year | -32.86% |
| 3-year | -76.86% |
| 5-year | N/A |
| YTD | -62.10% |
| 2021 | -32.80% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...